Peptide Schedule
Larazotide (AT-1001)8 residuesGGVLVQPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Larazotide (AT-1001) Dosage Calculator
Larazotide acetate (AT-1001) is a synthetic eight-amino-acid peptide (sequence: GGVLVQPG) derived from Vibrio cholerae's zonula occludens toxin.
0.5mcg · 3x Daily
Summary: Add 0mL BAC water to your 0.5mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.5mcg dose. This vial will last 0 doses.
Cycle Planner
Larazotide (AT-1001) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = Luminal activity ~1-4 hours (not systemically absorbed)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Larazotide (AT-1001) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.5mg | 3x Daily |
| Moderate | 0.5mg | 3x Daily |
| Aggressive | 1mg | 3x Daily |
Note: Larazotide is an oral peptide — one of the few peptides that doesn't require injection. It acts locally in the intestinal lumen and isn't absorbed into the bloodstream. Clinical trials used oral capsules dosed three times daily before meals. The 0.5 mg TID dose showed the strongest results in Phase 2b; higher doses (1 mg, 2 mg) didn't outperform placebo, suggesting an inverted dose-response. The Phase 3 CedLara trial was discontinued in June 2022 after interim analysis showed the effect size was too small to reach statistical significance with a feasible sample size. Despite this setback, larazotide remains the most clinically advanced tight junction regulator ever tested.
About Larazotide (AT-1001)
Larazotide acetate (AT-1001) is a synthetic eight-amino-acid peptide (sequence: GGVLVQPG) derived from Vibrio cholerae's zonula occludens toxin. It's the first-in-class tight junction regulator designed to treat celiac disease by reducing intestinal permeability — commonly called "leaky gut." Unlike most peptides, larazotide is taken orally as a capsule and works entirely within the gut lumen without entering the bloodstream. This local action gives it a clean safety profile with minimal systemic side effects. In Phase 2b trials involving 342 celiac patients on a gluten-free diet, the 0.5 mg three-times-daily dose significantly reduced GI symptoms compared to placebo, with a 26% decrease in symptomatic days and a 31% increase in improved symptom days. It's designed to complement — not replace — a gluten-free diet, targeting the roughly 40% of celiac patients who continue experiencing symptoms despite strict dietary adherence. The peptide blocks zonulin receptors on intestinal epithelial cells, preventing tight junction disassembly triggered by gluten-derived gliadin peptides. This keeps the paracellular space sealed, reducing the inflammatory cascade that drives celiac symptoms. Early trials also showed it could prevent the spike in intestinal permeability during controlled gluten challenges. However, the Phase 3 CedLara trial (525 patients) was discontinued in 2022 when interim analysis revealed the treatment effect was insufficient to reach significance with a practical sample size. 9 Meters Biopharma, the developer, subsequently analyzed subgroup data for potential responder populations. The drug's story highlights both the promise of oral peptide therapeutics and the difficulty of translating Phase 2 results into Phase 3 success.